Cervical Cancer Clinical Trials & Research

Clinical trials at Memorial Sloan Kettering may give you access to new therapies that aren’t widely available. These research studies evaluate the safety and effectiveness of new ways to diagnose and treat cervical cancer. They can also give your treatment team information about your current plan of care.

Our clinical research team is highly experienced in selecting women who are mostly likely to benefit from a particular investigational therapy and in guiding patients through the process of enrolling in the most appropriate clinical trial. If you are eligible to participate in a clinical trial, you may have access to new therapies that are not yet widely available.

A number of our trials focus on current standards for treatment and enhance survival and quality of life. These trials are done through our research programs as well as through the efforts of the Gynecologic Oncology Group, a multi-institutional clinical research effort supported by the National Cancer Institute.

Additional studies are under way to identify vaccines that target other types of HPV linked to cervical cancer, help your immune system destroy HPV if you’re already infected, and offer new treatments if you have advanced or recurrent cervical cancer. Ask your treatment team if you’re interested in learning more about these vaccines.

Currently Enrolling

The following cervical cancer clinical trials at Memorial Sloan Kettering are currently enrolling patients. To learn more about a study, choose from the list below.

and/or
9 Clinical Trials found
A Phase 1 Study of DAY301 in People With Advanced Solid Tumors
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of LY4170156 in People With Solid Tumors
Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1/2 Study of STAR0602 in People With Solid Tumors
Researchers in this study want to find the best dose of STAR0602 to use in people with advanced solid tumors. The people in this study have cancer that is inoperable (cannot be taken out with surgery) or metastatic (has spread). STAR0602 boosts the immune system to stop tumor growth. It is given intravenously (by vein).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Ivonescimab in People With Endometrial and Cervical Cancers
Researchers want to see how well ivonescimab works as a treatment for endometrial and cervical cancers. The people in this study have endometrial or cervical cancer that keeps growing after treatment.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Raludotatug Deruxtecan in People With Advanced Solid Tumors
Researchers want to see how well raludotatug deruxtecan (R-DXd) works against advanced solid tumors. The people in this study have the following cancers, which have spread despite treatment:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study of Induction Therapy Added to Chemoradiation and Pembrolizumab Maintenance Therapy for High-Risk Locally Advanced Cervical Cancer
The standard treatment for high-risk locally advanced cervical cancer is chemoradiation followed by maintenance therapy. Locally advanced means the cervical cancer has spread to nearby tissue or lymph nodes. In this study, researchers want to see if adding induction therapy before chemoradiation is more effective than standard therapy.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase II Study of Trastuzumab Deruxtecan in People with HER2-Positive Solid Tumors
The purpose of this study is to assess the safety and effectiveness of the drug trastuzumab deruxtecan (also known as DS-8201A) in patients with inoperable or metastatic solid tumors that produce too much of a protein called HER2, including biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers.
New York City, Westchester, Monmouth
A Study Comparing Robotic-Assisted Laparoscopy and Laparotomy for Radical Hysterectomy in People with Cervical Cancer
Radical hysterectomy via laparotomy (open surgery) is the standard surgical approach for people with early-stage cervical cancer. A radical hysterectomy involves removal of the uterus, cervix, parametria (tissue beside the cervix), and upper part of the vagina; the ovaries, fallopian tubes, and nearby lymph nodes may also be removed. With laparotomy, the operation is performed through a large incision in the abdomen.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Study of SLV-154 in People With Solid Tumor Cancer
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau